Related Experiment Video
Updated: Jun 8, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Bcl-2 expression and triple negative profile in breast carcinoma
Imen Kallel-Bayoudh1, Hanen Ben Hassen, Abdelmajid Khabir
1Bioinformatics and Signalling Unit, Centre of Biotechnology of Sfax, PO Box 1177, 3018 Sfax, Tunisia.
Medical Oncology (Northwood, London, England)
|October 5, 2010
Summary
BCL2 protein expression is a significant predictor of survival in breast cancer patients. This biomarker, alongside HER2 and oestrogen receptors (ER), can improve prognostic accuracy for breast cancer.
Area of Science:
- Oncology
- Biomarker Research
- Cancer Prognostics
Background:
- Established breast cancer biomarkers include HER2 and oestrogen receptors (ER).
- BCL2 is increasingly recognized for its prognostic value in breast cancer.
- Clinical utility of BCL2 requires further evaluation in conjunction with other markers.
Purpose of the Study:
- To investigate BCL2, HER2, ER, and progesterone receptor (PR) protein expression patterns.
- To assess the correlation of these biomarkers with patient survival.
- To evaluate associations with prognostic factors like tumor size, grade, and metastasis.
Main Methods:
- Retrospective study of 84 Tunisian women with breast cancer.
- Immunohistochemistry used for protein expression analysis.
- Statistical analysis including univariate, multivariate, and Bayesian network approaches.
Main Results:
- Expression rates: BCL2 (69%), HER2 (62%), ER (58.3%), PR (51.2%).
- BCL2 correlated significantly with PR, ER, and HER2 expression.
- BCL2 expression was positively associated with patient survival (P=0.032).
Conclusions:
- BCL2 expression is a valuable prognostic factor in breast cancer.
- Combining BCL2 with HER2 and ER can enhance breast cancer prognosis.
- BCL2 shows significant association with PR and ER in multivariate analysis.
